RecruitingNCT06490159

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer

Sponsor

City of Hope Medical Center

Enrollment

150 participants

Start Date

Oct 1, 2018

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer Chemotherapy Induced Peripheral Neuropathy Paclitaxel Ramucirumab

Summary

Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue and blood samples from people with advanced gastric (stomach) cancer who are being treated with paclitaxel chemotherapy, to try to identify biomarkers that predict who will develop nerve damage (peripheral neuropathy) as a side effect. **You may be eligible if...** - You are over 20 years old with confirmed advanced or recurrent gastric adenocarcinoma - Your cancer has progressed or you could not tolerate first-line chemotherapy with fluoropyrimidine and platinum drugs - You have measurable disease on imaging - Your general health status is sufficient for treatment (ECOG 0–2) **You may NOT be eligible if...** - You have already received paclitaxel-containing treatment - You already have significant nerve damage (neuropathy) - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.